NCT06235164 2024-01-31
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
Fujian Medical University
Unknown
Clinical Trials
14 trialsNCT03458455 2023-11-01
TREATMENT
Oslo University Hospital
Unknown
NCT05418660 2023-09-18
I-STOP
University of Milano Bicocca
Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT04359199 2023-02-10
QUASAR
University of California, San Diego
Unknown
NCT04465942 2021-08-23
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
European Lung Cancer Working Party
Unknown
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown
NCT04771715 2021-02-25
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Peking Union Medical College Hospital
Unknown
NCT04136470 2020-08-10
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
Ardigen
Unknown
NCT04145232 2020-08-10
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
Ardigen
Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT04306042 2020-03-12
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
Guangdong Association of Clinical Trials
Unknown
NCT04169867 2019-11-20
Polish Microbiome Map
Ardigen
Unknown
NCT03652142 2018-08-29
Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
Attikon Hospital
Unknown